Wegovy HD Secures FDA Approval Semaglutide 7.2 mg achieved 20.7% mean weight loss in STEP UP trials. By Kathryn Wighton March 19, 2026 2 min Conexiant Share Summary Takeaways Listen Insight Report Clinical Scorecard Quiz Poll Top Thought Leaders 1 The FDA approved semaglutide 7.2 mg (Wegovy HD) for obesity treatment based on the phase 3 STEP UP clinical trial results. 2 In the STEP UP trial, semaglutide 7.2 mg led to a mean weight loss of 20.7% among adults with obesity. 3 The STEP UP T2D trial showed a mean weight loss of 14.1% in adults with obesity and type 2 diabetes. 4 Wegovy HD is a once-weekly injectable therapy that also addresses cardiovascular risks and metabolic dysfunction. 5 Novo Nordisk plans to launch semaglutide 7.2 mg in a single-dose pen in the US by April 2026.
